Equillium to collaborate with Oxford University and Kennedy


LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced hui a translational research collaboration with the Kennedy Institute of Rheumatology and Sir William Dunn School of Pathology, University of Oxford. The research collaboration will investigate how CD6 monoclonal antibodies, such as itolizumab, modulate T cell responses and explore the role of the CD6-ALCAM pathway in rheumatic disease. CD6 is a co-stimulatory receptor, primarily expressed on T cells, that binds to the activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen-presenting cells and various epithelial and endothelial tissues . The CD6-ALCAM pathway plays an essential role in the modulation of T cell activation, proliferation, differentiation and trafficking and is believed to play a central role in many autoimmune disorders.

“A better understanding of the molecular interactions of the T cell receptor and CD6, and how it is regulated, will help improve therapeutic applications,” said Dr Marion H. Brown of the Sir William Dunn School of Pathology, University of Oxford. “Oxford is used to conducting research in the area of ​​CD6 biology and this collaboration with Equillium capitalizes on our expertise in characterizing how anti-CD6 antibodies modulate T cell responses at the molecular and cellular level. , with regard to the treatment of autoimmune and inflammatory diseases. diseases. “

The translational research collaboration aims to expand and strengthen the potential use of anti-CD6 therapies in patients with rheumatoid arthritis and other rheumatologic indications, one of the main areas of interest of the Kennedy Institute, which is the largest European university department in its field.

“Currently, less than a quarter of patients who receive standard anti-TNFα plus methotrexate therapy achieve remission and, in most cases, relapse upon discontinuation,” said Richard Williams, Ph.D. ., professor at the Kennedy Institute of Rheumatology, University of Oxford. “For this reason, continued efforts are needed to develop drugs capable of providing long-term remission from rheumatoid arthritis. This project with itolizumab will help develop a novel therapeutic strategy for rheumatoid arthritis that targets the CD6-ALCAM pathway, which we believe plays a key role in stimulating immune responses and reducing inflammation.

“We are delighted to be working with leading immunologists and rheumatologists from the prestigious Kennedy Institute and the University of Oxford, who have an interest and pedigree in conducting research in the biology of CD6,” said Stephen Connelly , Ph.D., Scientific Director of Equillium. “This collaboration illustrates Equillium’s commitment to advancing our understanding of the CD6-ALCAM pathway and how itolizumab could be used to treat a variety of autoimmune and inflammatory diseases.

About itolizumab
Itolizumab is a clinical first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells which are at the origin of a number of immuno-inflammatory diseases. Equillium acquired the rights to itolizumab through an exclusive partnership with Biocon Limited.

About the Kennedy Institute
The Kennedy Institute is part of the Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences (NDORMS), a multidisciplinary department focused on discovering the causes of musculoskeletal and inflammatory conditions in order to provide excellent and innovative care that improves the quality of life of people. The largest European academic department in its field, NDORMS is part of the Division of Medical Sciences at the University of Oxford and is a rapidly growing community of over 500 orthopedic surgeons, rheumatologists and scientists all working in the field of disorders. musculoskeletal.

The research work of the department takes place in several locations of the Nuffield Orthopedic Center, namely the Botnar Research Center, the Kennedy Institute of Rheumatology and the Kadoorie Center. Co-location with NHS services puts the department in an excellent position with foundational researchers working alongside clinicians. This dramatically improves research capacity, improves researchers’ access to patients, and facilitates the interaction between clinicians and scientists that is critical to the success of medical research. www.ndorms.ox.ac.uk

About Equillium
Equillium is a clinical-stage biotechnology company that draws on a deep understanding of immunobiology to develop new products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple serious immunoinflammatory diseases, including acute graft versus host disease (aGVHD), lupus / lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Forward-looking statements

Statements in this press release regarding matters which are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Since such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements. Such statements include, without limitation, statements regarding the potential benefit of treating patients with aGVH, uncontrolled asthma or lupus / lupus nephritis with itolizumab, the Equillium plans and the schedule. planned for the development of itolizumab, including the planned timeline for initiation, completion and further announcement of the results of the EQUATE, EQUIP and EQUALIZE studies, the potential for any ongoing or planned clinical studies to ” Equillium to show safety or efficacy, statements regarding the impact of new members of the management team, Equillium’s expected timeline for regulatory review and feedback, Equillium’s cash flow trail, and Equillium’s plans and expected timeline for the development of itolizumab and the potential benefits of itolizumab. Risks that contribute to the uncertain nature of forward-looking statements include: uncertainties relating to the ability of new members of the management team to integrate and perform as intended; the ability of Equillium to execute its plans and strategies; risks associated with performing clinical studies; the risk that the interim results of a clinical study do not necessarily predict the final outcome and that one or more of the clinical outcomes may change significantly as patient recruitment continues, as a result of more comprehensive reviews data and as more patient data becomes available; potential delays in the initiation, registration and completion of clinical studies and the reporting of resulting data; the risk that studies will not be completed as planned; Equillium’s plans and product development, including the initiation and completion of clinical studies and the reporting of resulting data; whether the results of clinical studies will validate and support the safety and efficacy of itolizumab; changes in the competitive landscape; uncertainties related to Equillium’s capital requirements; and having to use cash in a way or at a time other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are further described under the heading “Risk Factors” in Equillium’s Annual Report on Form 10-K for the year ended December 31, 2020, and elsewhere in Equillium’s documents and reports to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium makes no commitment to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor contact
Michael moore
Vice-President, Investor Relations and Corporate Communications
619-302-4431
[email protected]

Media contacts
Aljanae reynolds
Wheelhouse Life Sciences Advisors
[email protected]


About Hector Hedgepeth

Check Also

Dr. Vizarath Rasool Khan’s free mega medical camp ended successfully

Hyderabad: Dr. Vizarath Rasool Khan’s Free Mega Medical Camp at Shadan Hospital successfully ended on …

Leave a Reply

Your email address will not be published.